Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
FDA Has Issued New Postmarketing Requirement
LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval
THOUSAND OAKS, Calif., Dec. 26, 2023 -- (Healthcare Sales & Marketing Network) -- Amgen ... Biopharmaceuticals, Oncology, FDA Amgen, LUMAKRAS, sotorasib, non-small cell lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals